News 23.05.2024 Innovate UK (iUK), the United Kingdom (UK)'s national innovation agency, and Innosuisse, the Swiss counterpart, are co-founding a project to enhance innovation in cell and gene therapy (CGT) manufacturing. The project consortium includes Cell and Gene Therapy Catapult Limited from the UK, and Securecell AG, and DataHow AG from Switzerland. The...
News 21.05.2024 Switzerland, 17 May 2024 – CUTISS AG, a Swiss pioneering life sciences company specializing in skin regenerative medicine and tissue engineering, is glad to announce the first closing of CHF 25 million in its Series C funding round. This milestone demonstrates strong investor confidence in CUTISS’ mission and progress. The Series...
News 17.05.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address ("Molecular Partners" or...
News 16.05.2024 May 15, 2024, Zürich, Switzerland and Frankfurt, Germany In a significant expansion of its industry-leading portfolio, InSphero AG is pleased to announce its exclusive commercialization partnership with Genome Biologics, based in Frankfurt, Germany. This partnership will grant InSphero exclusive global rights to commercialize Genome Biologics' revolutionary 3D Cardiac Organoid Platform. This platform...
News 10.05.2024 SCHLIEREN, ZURICH, SWITZERLAND, May 9, 2024 /EINPresswire.com/ -- Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced the nomination of an anti-allergen multispecific antibody that is undergoing Investigative New Drug (IND)-enabling studies and subsequent clinical development for the treatment of peanut allergy. For the...